MOSCOW, RUSSIA--(Marketwired – February 26, 2015; Biospace - February 27, 2015) - Cromos™ Pharma, an international full-service CRO announced today that it launched Cardiorus, a state of the art cardiology and cardiothoracic surgery site research organization (SRO) with its clinical base being at the Bakoulev Institute of Cardiovascular Surgery in Moscow, Russia.
"The launch of Cardiorus gives us unprecedented capabilities to scale up both cardiology and cardiothoracic surgery drug and device studies," said Dr. Vlad Bogin, MD, FACP, company's CEO. "We've been actively collaborating with Bakoulev Institute for a number of years and are very excited about taking this relationship to a new level. This immense medical facility performs over 5000 open heart surgeries, 7500 PCIs and more than 11000 outpatient procedures."
"We are excited about the creation of Cardiorus," said Dr. Olga Bokeria, MD, PhD, Bakoulev Institute's Chief Scientist. "It will help streamline and standardize our work flows, reduce investigators' administrative burden and will help the Institute to conduct clinical research at a faster pace and with better quality."
Cromos™ Pharma, the parent organization, will provide administrative, logistical and project management support, quality assurance training and oversight services for Cardiorus.
About Cromos™ Pharma, LLC
Cromos™ Pharma, LLC is a contract research organization (CRO) with operations in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company.